dimerizing agent-regulated immunoreceptor complex-expressing CD33-specific autologous CAR T cells SC-DARIC33
Term · Oncology and biomedicine · MLC-T-ONC-013058
A preparation of equal amounts of autologous CD4-positive and CD8-positive T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD33 and genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC), with potential immunomodulating and antineoplastic activities. Upon transfusion of the DARIC-expressing CD33-specific autologous CAR T cells SC-DARIC33 and followed by intermittent low dose rapamycin administration, rapamycin binds to DARIC and activates the T cells when binding to CD33-expressing tumor cells, thereby inducing selective toxicity in CD33-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and on myeloid leukemia cells. The ability of rapamycin to control the activity of the DARIC cells may help control the toxicity of the CAR T cells, prevent T-cell exhaustion and may help them last longer in vivo. Using the DARIC platform, the antigen recognition and signaling functions of a CAR are separated into two distinct polypeptides and engineered to contain the two interacting and dimerization domains, FK506-binding protein (FKPB12) and FKBP12-rapamycin-binding (FRB) protein. In the absence of the dimerizing drug rapamycin, the CAR T cells lack signaling activity upon antigen recognition and binding. The administration of the dimerizing agent enables the two DARIC subunits to interact and thereby allows for the CAR T cells to fully function and activate their signaling abilities upon antigen recognition.
| Identifier | MLC-T-ONC-013058 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | DARIC33 autologous CAR T cells SC-DARIC33; DARIC-expressing anti-CD33 CAR T cells SC-DARIC33; DARIC-expressing CD33-specific autologous CAR T cells SC-DARIC33; Seattle Children's DARIC33 autologous CAR T cells SC-DARIC33 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013058",
"term": "dimerizing agent-regulated immunoreceptor complex-expressing CD33-specific autologous CAR T cells SC-DARIC33",
"field": "Oncology and biomedicine",
"definition": "A preparation of equal amounts of autologous CD4-positive and CD8-positive T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD33 and genetically modified to express a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC), with potential immunomodulating and antineoplastic activities. Upon transfusion of the DARIC-expressing CD33-specific autologous CAR T cells SC-DARIC33 and followed by intermittent low dose rapamycin administration, rapamycin binds to DARIC and activates the T cells when binding to CD33-expressing tumor cells, thereby inducing selective toxicity in CD33-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and on myeloid leukemia cells. The ability of rapamycin to control the activity of the DARIC cells may help control the toxicity of the CAR T cells, prevent T-cell exhaustion and may help them last longer in vivo. Using the DARIC platform, the antigen recognition and signaling functions of a CAR are separated into two distinct polypeptides and engineered to contain the two interacting and dimerization domains, FK506-binding protein (FKPB12) and FKBP12-rapamycin-binding (FRB) protein. In the absence of the dimerizing drug rapamycin, the CAR T cells lack signaling activity upon antigen recognition and binding. The administration of the dimerizing agent enables the two DARIC subunits to interact and thereby allows for the CAR T cells to fully function and activate their signaling abilities upon antigen recognition.",
"synonyms": [
"DARIC33 autologous CAR T cells SC-DARIC33",
"DARIC-expressing anti-CD33 CAR T cells SC-DARIC33",
"DARIC-expressing CD33-specific autologous CAR T cells SC-DARIC33",
"Seattle Children's DARIC33 autologous CAR T cells SC-DARIC33"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/dimerizing-agent-regulated-immunoreceptor-complex-expressing-cd33-specific-car-t/"
}
Record 6,023 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.